Ye Shuang, Zhou Shuling, Chen Wei, Xiang Libing, Wu Xiaohua, Yang Huijuan
Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Cancer Manag Res. 2020 Feb 7;12:913-919. doi: 10.2147/CMAR.S242129. eCollection 2020.
To evaluate the recurrence patterns and survival outcomes of surgically treated relapsed ovarian clear cell carcinoma (OCCC) patients.
We performed a comprehensive retrospective analysis of all the patients who underwent secondary debulking from 2004/10 to 2019/04.
In total, 45 eligible patients were included. 75.6% of the patients had early-stage disease and platinum-sensitive recurrence accounted for 70.5%. The median progression-free survival after primary surgery (PFS 1) was 20 months (range, 2-137). Of all, 64.4% patients had solitary recurrence and 86.7% patients had no residual disease after secondary surgery. Regarding tumor distribution, the most common site was pelvis (47.5%), followed by lymph node metastases (18.0%) and abdominal wall lesions (8.2%). For the entire population, the median disease-free survival after recurrence (PFS 2) and post-relapse survival (PRS) was 15 months (range, 0-96), and 24 months (range, 3-159), respectively. Eight patients (17.8%) had a prolonged PFS2 more than 30 months. Patients with localized relapse had better survival including PFS 2 (=0.023), PRS (=0.004), and overall survival (OS) (=0.029). Patients who achieved complete resection tended to have longer PFS 2 (=0.017). After multivariate analysis, complete resection at recurrence remained as an independent positive predictor for PFS 2 (=0.022). The median OS was 50 months and was significantly associated with platinum response (=0.003) and number of relapsed lesions (=0.002).
A high rate of pelvic recurrence was noted in this population. Patients with focal recurrence had a favorable prognosis. Complete resection at secondary debulking proved to be an independent predictor for disease-free survival.
评估手术治疗复发卵巢透明细胞癌(OCCC)患者的复发模式和生存结局。
对2004年10月至2019年4月期间接受二次减瘤手术的所有患者进行全面回顾性分析。
共纳入45例符合条件的患者。75.6%的患者为早期疾病,铂敏感复发占70.5%。初次手术后的中位无进展生存期(PFS1)为20个月(范围2 - 137个月)。其中,64.4%的患者为孤立性复发,86.7%的患者二次手术后无残留病灶。关于肿瘤分布,最常见的部位是盆腔(47.5%),其次是淋巴结转移(18.0%)和腹壁病变(8.2%)。对于全体患者,复发后的中位无病生存期(PFS2)和复发后生存期(PRS)分别为15个月(范围0 - 96个月)和24个月(范围3 - 159个月)。8例患者(17.8%)的PFS2延长超过30个月。局部复发的患者生存情况较好,包括PFS2(P = 0.023)、PRS(P = 0.004)和总生存期(OS)(P = 0.029)。实现完全切除的患者PFS2往往更长(P = 0.017)。多因素分析后,复发时的完全切除仍然是PFS2的独立阳性预测因素(P = 0.022)。中位OS为50个月,与铂类反应(P = 0.003)和复发病灶数量(P = 0.002)显著相关。
该人群盆腔复发率较高。局灶性复发的患者预后良好。二次减瘤手术时的完全切除被证明是无病生存期的独立预测因素。